Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff et al
- PMID: 34272251
- DOI: 10.1136/annrheumdis-2021-220764
Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff et al
Keywords: COVID-19; rituximab; vaccination.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.Ann Rheum Dis. 2021 Oct;80(10):e159. doi: 10.1136/annrheumdis-2021-220539. Epub 2021 May 24. Ann Rheum Dis. 2021. PMID: 34031031 No abstract available.
-
Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.Ann Rheum Dis. 2021 Oct;80(10):e158. doi: 10.1136/annrheumdis-2021-220496. Epub 2021 May 28. Ann Rheum Dis. 2021. PMID: 34049854 No abstract available.
-
Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.Ann Rheum Dis. 2021 Oct;80(10):e160. doi: 10.1136/annrheumdis-2021-220736. Epub 2021 Jun 10. Ann Rheum Dis. 2021. PMID: 34112654 Free PMC article. No abstract available.
-
Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.Ann Rheum Dis. 2021 Oct;80(10):e161. doi: 10.1136/annrheumdis-2021-220898. Epub 2021 Jun 29. Ann Rheum Dis. 2021. PMID: 34187777 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous